Sentence examples for differences in the trail from inspiring English sources

Differences in the Trail Making Test Part B were, again, nonsignificant between the two groups.

Despite the clear advantages of in vivo systems to address our question, they could not be used due to the significant differences in the TRAIL receptor family as well as the regulation of TRAIL sensitivity between human and rodent cells.

There were significant overall group differences in the Trail Making Test B, the WMS-R Visual Reproduction test, the WAIS Digit Symbol test, and the composite z score (p's ≤ 0.040; Table  3).

There was no difference in the TRAIL mRNA gene expression ratio between MS patients and controls.

Statistically significant differences in secondary endpoints were similarly modest, and there was no difference in the Trail Making Test Part B. Of note, the only hard clinical endpoint in any of the three trials – days alive and out of the hospital at 60 days, was not different between the two groups.

The serum TRAIL level was lower in MS patients compared to controls but no difference was seen in the TRAIL mRNA gene expression ratio.

The simulations thus support the idea that in the ATP concentration range used in the experiments, the differences in the interactions of the trailing and leading ends of the myofilament with actin can generate compressive forces on the actin filament, and that these forces are sufficiently high to bend and break the actin filament.

Koornstra et al (2003) also reported overall expression of TRAIL receptors, which have a large cytoplasmic component, to be similar in adenoma and carcinoma cells; therefore, immunohistochemical studies have not revealed a mechanism for the differences in TRAIL sensitivity between the adenoma and carcinoma cells.

Two-sample t-test and one-way ANOVA were used to determine the statistical significance of the differences in TRAIL and its receptors expression levels in OPM and OSCC with various clinicopathologic parameters.

The difference in sensitivity to TRAIL- and FasL-mediated apoptosis between early-cultured and confluent RASFs is not due to differences in the surface expression of Fas and TRAIL receptors.

This is likely due to differences in the concentrations of both drug and TRAIL conditions that were employed in these other studies; for example, other studies have employed 100 ng/mL TRAIL, which is ten-fold higher than the concentration used in our study [ 26, 41].